Olopatadine

Olopatadine
Systematic (IUPAC) name
	{(11Z)-11-[3-(dimethylamino)propylidene]-6,11-; dihydrodibenzob,eoxepin-2-yl}acetic acid
Clinical data
Trade names	Patanol
AHFS/Drugs.com	monograph
MedlinePlus	a602025
Pregnancy cat.	C
Legal status	?
Routes	Ophthalmic, intranasal, oral
Pharmacokinetic data
Half-life	3 hours
Identifiers
CAS number	113806-05-6
ATC code	S01GX09 R01AC08
PubChem	CID 5281071
DrugBank	DB00768
ChemSpider	4444528
UNII	D27V6190PM
KEGG	D08293
ChEMBL	CHEMBL1189432
Chemical data
Formula	C21H23NO3
Mol. mass	337.412 g/mol
SMILES	eMolecules & PubChem
	InChI InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8- ; Key:JBIMVDZLSHOPLA-LSCVHKIXSA-N ;
(what is this?) (verify);

Olopatadine hydrochloride is an antihistamine (as well as anticholinergic) and mast cell stabilizer, sold as a prescription eye drop (0.2% solution, Pataday (or Patanol S in some countries), manufactured by Alcon). It is used to treat itching associated with allergic conjunctivitis (eye allergies). Olopatadine hydrochloride 0.1% is sold as Patanol (or Opatanol in some countries). A nasal spray formulation is sold as Patanase, which was approved by the FDA on April 15, 2008.¹ It is also available as an oral tablet in Japan under the tradename Allelock, manufactured by Kyowa Hakko Kogyo.²

It should not be used to treat irritation caused by contact lenses. The usual dose for Patanol is 1 drop in each affected eye 2 times per day, with 6 to 8 hours between doses.

Its side effects may include headaches (7% of occurrence) burning and stinging (5%), dry eye, foreign body sensation, hyperemia, keratitis, lid edema, pruritus, asthenia, cold syndrome, pharyngitis, rhinitis, sinusitis, and taste perversion.

There is potential for Olopatadine as a treatment modality for steroid rebound (red skin syndrome.) ³

Olopatadine was developed by Kyowa Hakko Kogyo.⁴

References

^ Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
^ Kyowa Hakko Kogyo Co., Ltd. (2007). "ALLELOCK Tablets 2.5 & ALLELOCK Tablets 5 (English)" (PDF). http://www.e-search.ne.jp/~jpr/PDF/KYOWA08.PDF. Retrieved 2008-08-10.
^ Tamura T, Matsubara M, Hasegawa K, Ohmori K, Karasawa A. (2005). "Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity.". http://www.ncbi.nlm.nih.gov/pubmed/15649273.
^ Kyowa Hakko Kogyo Co., Ltd. (2002). "Company History". Company Information. Kyowa Hakko Kogyo Co., Ltd.. http://www.kyowa-kirin.co.jp/english/company/history/index.html. Retrieved 16 September 2010.

External links

Pataday website
Patanase website
Olopatadine Ophthalmic via MedlinePlus

[0] Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms

[KYOWA08-1] Kyowa Hakko Kogyo Co., Ltd. (2007). "ALLELOCK Tablets 2.5 & ALLELOCK Tablets 5 (English)" (PDF). http://www.e-search.ne.jp/~jpr/PDF/KYOWA08.PDF. Retrieved 2008-08-10.

[2] Tamura T, Matsubara M, Hasegawa K, Ohmori K, Karasawa A. (2005). "Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity.". http://www.ncbi.nlm.nih.gov/pubmed/15649273.

[3] Kyowa Hakko Kogyo Co., Ltd. (2002). "Company History". Company Information. Kyowa Hakko Kogyo Co., Ltd.. http://www.kyowa-kirin.co.jp/english/company/history/index.html. Retrieved 16 September 2010.

...the chemical, pharmaceutical and food-additives trading company

Olopatadine

References

External links

Search Box